Advancements in Breast Cancer Genetic Testing for Women of African Ancestry

The Crisis in Breast Cancer Mortality

In recent years, genetic testing has radically changed our ability to understand and predict breast cancer risk. Yet, a troubling disparity remains: women of African ancestry suffer disproportionately high mortality rates from breast cancer. This stark reality can be traced to several factors, including the limitations of existing genetic risk prediction models, the higher prevalence of aggressive tumor types—particularly triple-negative breast cancer (TNBC)—and the tendency for later-stage diagnoses in these populations. These challenges highlight an urgent need for more tailored and accurate predictive tools designed specifically for women of African descent.

The University of Chicago Medicine’s Groundbreaking Initiative

The University of Chicago Medicine has taken significant steps to address these disparities by developing a new set of polygenic risk score (PRS) models specifically for women of African ancestry. This innovative research analyzed genetic data from over 36,000 women across the United States, the Caribbean, and Sub-Saharan Africa, constructing what is now considered the most comprehensive and accurate breast cancer prediction framework for this historically underserved group. Published in Nature Genetics, this work represents a major advancement in bridging gaps in personalized medicine.

The Shortcomings of Previous Models

One key reason previous genetic risk models have struggled for African American women is that they were primarily based on data collected from white women of European ancestry. While these models perform well within similar genetic backgrounds, they falter when applied to populations with distinct genetic profiles. African ancestry populations possess considerable genomic heterogeneity, leading to diverse genetic variants that may significantly influence breast cancer risk yet have been overlooked by past models. Consequently, earlier predictive tools showed suboptimal accuracy for women of African descent.

Understanding Polygenic Risk Scores

Polygenic risk scores measure an individual’s genetic susceptibility to diseases by aggregating the effects of thousands of single nucleotide polymorphisms (SNPs). These SNPs represent tiny variations in the DNA sequence. Although a single SNP may not significantly influence risk, the cumulative impact can be substantial. The new PRS models developed by the University of Chicago have corrected deficiencies by capturing important African-specific SNPs, leading to more precise estimations of breast cancer risk across various tumor types.

A Consortium-Driven Approach

The researchers took a rigorous consortium-driven approach, pooling genetic information through the African Ancestry Breast Cancer Genetics Consortium, which includes 20 research institutions. They categorized breast cancer into four types for analysis: overall incidence, estrogen receptor-positive (ER+), estrogen receptor-negative (ER-), and the aggressive TNBC subtype. Employing the area under the curve (AUC) metric to evaluate predictive performance, the new PRS models achieved AUC values between 0.61 and 0.64, surpassing earlier models that were stuck between 0.56 and 0.58. This marks a significant leap forward in predictive accuracy.

Clinical Feasibility and Simplification

The research team didn’t just focus on accuracy; they also prioritized clinical feasibility by developing simplified risk models. Notably, they created a TNBC-specific score using just 162 genetic markers, yet it achieved an AUC of 0.626. This streamlined approach means that comprehensive risk assessments can be both practical and cost-effective, paving the way for broader implementation and improved early screening strategies for women at higher risk.

The Importance of Early Detection

Early detection is crucial for improving outcomes in breast cancer treatment. With these enhanced PRS models, healthcare providers can identify high-risk women much earlier and customize screening protocols to suit individual risk profiles. Strikingly, the analysis indicates that women in the top 1% of overall risk scores have a lifetime breast cancer risk of 25.7%. Those at the highest risk for TNBC face a 7.4% chance of developing this aggressive form. These insights could justify starting screenings earlier than the current recommendations, potentially lowering the threshold to as soon as 32 years for those classified as being at extreme risk.

Integrating Family History for Better Prediction

The research further refines predictive power by integrating family history, a well-known risk factor for breast cancer. Women ranking in the top 1% of PRS who also have a first-degree relative with breast cancer face a staggering lifetime risk exceeding 50%. This synthesis of genetic and familial data underscores a precision medicine approach, suggesting enhanced monitoring and proactive treatment strategies for those at elevated risk.

Robust Validation Across Cohorts

Validation of the newly established PRS models has been comprehensive, involving multiple independent cohorts, including the “All of Us” Research Program and other studies featuring women of African descent. Impressively, the TNBC model’s AUC reached 0.652 in an external cohort, reinforcing its reliability across diverse populations of African ancestry. This cross-validation is vital for confirming the applicability of these tools, positioning them for broader clinical acceptance.

Future Directions and Expanding Research

While this trailblazing research primarily targets African American women and those of West African ancestry, the investigators emphasize the need for further studies throughout the African continent. Africa’s immense genetic diversity necessitates tailored risk model refinements for different regional populations. In addition, incorporating data from global African diaspora communities will enhance the effectiveness and inclusivity of breast cancer risk predictions worldwide.

The Broader Impact of Enhanced Polygenic Risk Scores

The implications of these improved polygenic risk scores extend beyond mere statistical figures. They exemplify a future where genetic testing informed by ancestry becomes standard, significantly reducing healthcare disparities. Through improved early detection, targeted interventions, and personalized treatment strategies, these advancements could lead to much better survival rates and enhanced quality of life for African-descended women, who have long been underserved by the traditional healthcare system.

A Collaborative Effort for Change

This ambitious research was made possible through generous support from leading institutions like the National Institutes of Health, the Breast Cancer Research Foundation, and the Susan G. Komen Foundation. It highlights the power of multi-institutional collaborations in tackling complex health inequities, bringing together experts from genetics, epidemiology, clinical practice, and statistics to drive forward innovative approaches in breast cancer care.

Publication and Author Details

The research findings were published in the prestigious Nature Genetics journal on February 2, 2026. Lead author James L. Li, a dedicated medical scientist trainee, played a pivotal role alongside senior author Dezheng Huo, PhD, and a diverse team of collaborators from universities and research institutions around the globe. Their collective efforts represent a paradigm shift in leveraging genomic data to empower historically marginalized communities toward better health outcomes.

A Call to Embrace Genetic Diversity

This significant advancement underscores the importance of embracing genetic diversity to develop population-specific tools, overcoming the limitations of one-size-fits-all models. As genomic research continues to evolve, such initiatives will be critical for achieving equitable healthcare, ensuring that cutting-edge discoveries benefit all populations rather than a privileged few.